MiNK Therapeutics, Inc. extended cash runway to advance clinical program in GVHD, with Ph2 results expected in 2L Gastric Cancer. Department of Defense STTR Grant awarded to advance INKTs in GVHD program, while a new clinical grant was provided to launch AgenT-797 in GvHD clinical trial with target initiation in 2H2025.

Key highlights from Q2 2025 include a durable complete remission in metastatic testicular cancer with agenT-797, strengthened balance sheet with increased cash reserves, and grants awarded for GvHD programs. Progress in Phase 2 Gastric Cancer Study anticipated more clinical readouts in 2025, and a peer-reviewed review highlighted iNKT cell therapy advancements.

Financially, MiNK ended Q2 2025 with $1.6 million in cash and raised $13 million through equity sales. Net loss for Q2 2025 was $4.2 million, with ongoing activities supporting agent-797 programs. MiNK will host a conference call and webcast on August 14, 2025, at 8:30 a.m. ET to discuss these updates.

MiNK Therapeutics is a clinical-stage biopharmaceutical company specializing in allogeneic iNKT cell therapies for cancer and other immune-mediated diseases. The company is headquartered in New York, NY, with a pipeline of native and engineered iNKT programs aimed at scalable and reproducible manufacturing for off-the-shelf delivery.

Investor and media contacts are available for more information about MiNK Therapeutics and its advancements in iNKT cell therapy. For more details, visit their website or social media channels. Forward-looking statements in this press release are subject to risks and uncertainties, with updates provided as necessary.

Read more at GlobeNewswire: MiNK Therapeutics Reports Clinical and Strategic Milestones